Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099311124> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2099311124 endingPage "AB171" @default.
- W2099311124 startingPage "AB171" @default.
- W2099311124 abstract "RATIONALE: Benefits of inhaled corticosteroids plus long-acting beta-agonists in asthma are well established. Little is known about the optimal timing of initiation after an acute asthma exacerbation. METHODS: Retrospective cohort study that compared the risk of asthma-related exacerbations (hospitalization, emergency department (ED) visit, and/or use of systemic corticosteroids) in patients receiving early versus late treatment with FSC following an initial asthma-related exacerbation. Data from a large health insurance claims dataset spanning January 1998-April 2008. Subjects with ≥1 prescription for FSC ≤1 year after first asthma-related exacerbation were identified. Patients who received treatment with FSC within 90 days after their exacerbation (“early treatment”) were propensity-score matched to those receiving FSC > 90 days after (“late treatment”). Healthcare utilization and costs after initiation of FSC were compared. RESULTS: 14,861 patients met inclusion criteria, 10,793 early and 4,068 late treatment patients. After matching there were 3555 in each group. Pairs were well matched on all pretreatment characteristics and duration of follow-up (mean 722 vs. 717 days, p=.634). Early treatment was associated with longer time to subsequent asthma-related exacerbation (Hazard ratio=0.82, 95%CI 0.75-0.88, p<0.001), fewer short-acting beta-agonists prescriptions (3.3 vs. 3.6, p=0.031) lower asthma-related ED visit costs ($80 vs. $105, p=0.032) and higher total outpatient pharmacy costs ($1,320 vs. $1,163, p=0.008). Total costs were similar across groups ($2,197 vs. $2,064, p=0.203). CONCLUSIONS: Earlier treatment with FSC following an asthma exacerbation was associated with reduced risk of subsequent asthma-related exacerbations and lower use of rescue medications over 2 years of FSC therapy." @default.
- W2099311124 created "2016-06-24" @default.
- W2099311124 creator A5038694515 @default.
- W2099311124 creator A5053240270 @default.
- W2099311124 creator A5077816696 @default.
- W2099311124 date "2010-02-01" @default.
- W2099311124 modified "2023-09-27" @default.
- W2099311124 title "Earlier Use Of Fluticasone Propionate/Salmeterol Combination (FSC) After An Asthma Exacerbation Reduces Subsequent Exacerbations Of Asthma And Albuterol Use" @default.
- W2099311124 doi "https://doi.org/10.1016/j.jaci.2009.12.669" @default.
- W2099311124 hasPublicationYear "2010" @default.
- W2099311124 type Work @default.
- W2099311124 sameAs 2099311124 @default.
- W2099311124 citedByCount "0" @default.
- W2099311124 crossrefType "journal-article" @default.
- W2099311124 hasAuthorship W2099311124A5038694515 @default.
- W2099311124 hasAuthorship W2099311124A5053240270 @default.
- W2099311124 hasAuthorship W2099311124A5077816696 @default.
- W2099311124 hasBestOaLocation W20993111241 @default.
- W2099311124 hasConcept C104863432 @default.
- W2099311124 hasConcept C118552586 @default.
- W2099311124 hasConcept C126322002 @default.
- W2099311124 hasConcept C167135981 @default.
- W2099311124 hasConcept C17923572 @default.
- W2099311124 hasConcept C187212893 @default.
- W2099311124 hasConcept C207103383 @default.
- W2099311124 hasConcept C2426938 @default.
- W2099311124 hasConcept C2776042228 @default.
- W2099311124 hasConcept C2776719499 @default.
- W2099311124 hasConcept C2776804153 @default.
- W2099311124 hasConcept C2777014857 @default.
- W2099311124 hasConcept C2779028295 @default.
- W2099311124 hasConcept C2780724011 @default.
- W2099311124 hasConcept C2781212218 @default.
- W2099311124 hasConcept C2909082789 @default.
- W2099311124 hasConcept C44249647 @default.
- W2099311124 hasConcept C512399662 @default.
- W2099311124 hasConcept C71924100 @default.
- W2099311124 hasConcept C98274493 @default.
- W2099311124 hasConceptScore W2099311124C104863432 @default.
- W2099311124 hasConceptScore W2099311124C118552586 @default.
- W2099311124 hasConceptScore W2099311124C126322002 @default.
- W2099311124 hasConceptScore W2099311124C167135981 @default.
- W2099311124 hasConceptScore W2099311124C17923572 @default.
- W2099311124 hasConceptScore W2099311124C187212893 @default.
- W2099311124 hasConceptScore W2099311124C207103383 @default.
- W2099311124 hasConceptScore W2099311124C2426938 @default.
- W2099311124 hasConceptScore W2099311124C2776042228 @default.
- W2099311124 hasConceptScore W2099311124C2776719499 @default.
- W2099311124 hasConceptScore W2099311124C2776804153 @default.
- W2099311124 hasConceptScore W2099311124C2777014857 @default.
- W2099311124 hasConceptScore W2099311124C2779028295 @default.
- W2099311124 hasConceptScore W2099311124C2780724011 @default.
- W2099311124 hasConceptScore W2099311124C2781212218 @default.
- W2099311124 hasConceptScore W2099311124C2909082789 @default.
- W2099311124 hasConceptScore W2099311124C44249647 @default.
- W2099311124 hasConceptScore W2099311124C512399662 @default.
- W2099311124 hasConceptScore W2099311124C71924100 @default.
- W2099311124 hasConceptScore W2099311124C98274493 @default.
- W2099311124 hasIssue "2" @default.
- W2099311124 hasLocation W20993111241 @default.
- W2099311124 hasOpenAccess W2099311124 @default.
- W2099311124 hasPrimaryLocation W20993111241 @default.
- W2099311124 hasRelatedWork W1969372887 @default.
- W2099311124 hasRelatedWork W1989275727 @default.
- W2099311124 hasRelatedWork W2099311124 @default.
- W2099311124 hasRelatedWork W2289536414 @default.
- W2099311124 hasRelatedWork W2353061216 @default.
- W2099311124 hasRelatedWork W2382700242 @default.
- W2099311124 hasRelatedWork W2405439450 @default.
- W2099311124 hasRelatedWork W2551909281 @default.
- W2099311124 hasRelatedWork W3035784203 @default.
- W2099311124 hasRelatedWork W4251304396 @default.
- W2099311124 hasVolume "125" @default.
- W2099311124 isParatext "false" @default.
- W2099311124 isRetracted "false" @default.
- W2099311124 magId "2099311124" @default.
- W2099311124 workType "article" @default.